IP Library Granted Patent US 9,919,079
Granted Patent B2
US 9,919,079 · App. 15/386,960 · Granted Mar 20, 2018

Cardiovascular prostheses

Inventor: Robert G Matheny (Norcross, GA)
Assignee: CorMatrix Cardiovascular, Inc.
A61L27/3633A61F2/0095A61F2/24A61K9/0024A61K31/4418A61K31/7036A61K38/14A61L27/18A61L27/54A61F2/02A61F2210/0004A61F2210/0076A61L2300/41A61L2300/414A61L2430/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,919,079
App. No.
15/386,960
Granted
Mar 20, 2018
Kind
B2
Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

Claims (4)

1. A particulate biomaterial composition for treating damaged cardiovascular tissue, comprising:

first particulates comprising acellular extracellular matrix (ECM) derived from a mammalian tissue source, second particulates comprising poly(glycerol sebacate) (PGS), and a plurality of exosomes, said plurality of exosomes encapsulating at least one biologically active agent selected from the group consisting of transforming growth factor-beta (TGF-β), vascular epithelial growth factor (VEGF), insulin-like growth factor (IGF-I) and interleukin-8 (IL-8),

said particulate biomaterial composition being adapted to modulate inflammation of damaged cardiovascular tissue and induce cell and tissue proliferation, bioremodeling of said damaged cardiovascular tissue, and regeneration of new cardiovascular tissue and tissue structures with site-specific structural and functional properties, when said particulate biomaterial composition is disposed proximate said damaged cardiovascular tissue.

2. The particulate biomaterial composition of claim 1 , wherein said decellularized mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS), mesothelial tissue, placental tissue and cardiac tissue.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070482/0001 →
CHANGE OF NAME Recorded Sep 15, 2023
From: AZIYO MED, LLC
To: ELUTIA MED LLC
Reel/Frame 064923/0704 →
CHANGE OF NAME Recorded Sep 15, 2023
From: AZIYO BIOLOGICS, INC.
To: ELUTIA INC.
Reel/Frame 064923/0361 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2022
From: AZIYO BIOLOGICS, INC.; AZIYO MED, LLC
To: MIDCAP FUNDING IV TRUST
Reel/Frame 061164/0532 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2022
From: AZIYO BIOLOGICS, INC.; AZIYO MED, LLC
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061161/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2021
From: AZIYO MED, LLC
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 055941/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2017
From: CORMATRIX CARDIOVASCULAR, INC.
To: AZIYO MED, LLC
Reel/Frame 042577/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2016
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 040746/0242 →
Continuity (2)
Continuation In Part 13328287 · Dec 16, 2011
Related Publication 20170100518A1 · Apr 13, 2017